Intravascular delivery of nucleic acid
View Patent ↗Disclosed is a process for transfecting genetic material into a mammalian cell to alter endogenous properties of the cell. The process comprises designing a polynucleotide for transfection. Then the polynucleotide is inserted into a mammalian blood vessel. Prior to insertion, subsequent to insertion, or concurrent with insertion the permability of the vessel is increased using an exterior cuff and immunosuppression is applied thereby the genetic material is delivered to the parenchymal cell.
1. A process for delivering a polynucleotide to a skeletal muscle cell of a mammal in vivo, comprising:
a) applying non-invasive external pressure against the skin of a limb of the mammal such that blood flow to and from the limb is impeded;
b) inserting the polynucleotide encoding a protein operably linked to a promoter in a solution into a blood vessel in the limb in vivo distal to the applied pressure; and,
c) administering immunosuppressive drugs to the mammal;
thereby delivering the polynucleotide to the skeletal muscle cell in the limb distal to the applied pressure and expressing the polynucleotide in the skeletal muscle cell at detectable levels.
2. The process of claim 1 wherein the polynucleotide consists of naked DNA.
3. The process of claim 1 wherein the polynucleotide is selected from the group consisting of a viral vector and a non-viral vector.
4. The process of claim 1 wherein the limb skeletal muscle cell consists of a leg skeletal muscle cell.
5. The process of claim 4 wherein the leg skeletal muscle cell is selected from the group consisting of gastrocnemius muscle cell and soleus muscle cell.
6. The process of claim 4 wherein the leg skeletal muscle cell is selected from the group consisting of popliteus muscle cell, flexor digitorum longus muscle cell, flexor hallucis longus muscle cell, and tibialis posterior muscle cell.
7. The process of claim 4 wherein the leg skeletal muscle cell consists of a foot skeletal muscle cell.
8. The process of claim 7 wherein the foot skeletal muscle cell is selected from the group consisting of extensor digitorum brevis muscle cell and extensor hallucis brevis muscle cell.
9. The process of claim 4 wherein the leg skeletal muscle cell is selected from the group consisting of tibialis anterior muscle cell, extensor hallucis longus muscle cell, extensor digitorum longus muscle cell, and abductor hallucis longus muscle cell.
10. The process of claim 4 wherein the leg skeletal muscle cell is selected from the group consisting of peronaus longus muscle cell and peronaus brevis muscle cell.
11. The process of claim 1 wherein the limb skeletal muscle cell consists of an arm skeletal muscle cell.
12. The process of claim 11 wherein the arm skeletal muscle cell is selected from the group consisting of palmaris longus muscle cell, pronator teres muscle cell, flexor carpi radialis muscle cell, flexor carpi ulnaris muscle cell, and flexor digitorum superficialis muscle cell.
13. The process of claim 11 wherein the arm skeletal muscle cell is selected from the group consisting of flexor digitorum profundus muscle cell, and pronator quadratus muscle cell.
14. The process of claim 11 wherein the arm skeletal muscle cell is selected from the group consisting of brachioradialis muscle cell, extensor carpi radialis longus muscle cell, extensor carpi radialis brevis muscle cell, extensor digitorum muscle cell, anconeus muscle cell, extensor carpi ulnaris muscle cell, and extensor pollicis longus muscle cell.
15. The process of claim 11 wherein the arm skeletal muscle cell is selected from the group consisting of supinator muscle cell, abductor pollicis longus muscle cell, extensor digiti secund et teriti muscle cell, and extensor digit quart et minimi muscle cell.
16. The process of claim 11 wherein the arm skeletal muscle cell consists of a hand skeletal muscle cell.
17. The process of claim 16 wherein the hand skeletal muscle cell consists of a thumb muscle cell.
18. The process of claim 16 wherein the hand skeletal muscle cell is consists of an interosseus muscle cell.
19. The process of claim 1 wherein applying non-invasive external pressure against the skin of the limb consists of applying a tourniquet around the limb.
20. The process of claim 1 wherein applying non-invasive external pressure against the skin of the limb consists of applying a cuff.
21. The process of claim 20 wherein the cuff consists of a sphygmomanometer.
22. The process of claim 1 wherein administering immunosuppressive drugs consists of repetitive administration of immunosuppressive drugs.
23. The process of claim 1 wherein administering immunosuppressive drugs consists of administering immunosuppressive drugs within one dya of injecting the polynucleotide.
24. The process of claim 1 wherein administering immunosuppressive drugs is selected from the group consisting of administering immunosuppressive drugs orally and administering immunosuppressive drugs by subcutaneous injection.
25. A process for delivering a polynucleotide to a skeletal muscle cell of a mammal in vivo, comprising:
a) applying pressure non-invasively against the skin of the limb thereby impeding blood flow into and out of the limb;
b) inserting the polynucleotide encoding an expressible sequence operably linked to a promoter in a solution into a blood vessel in the limb of the mammal in vivo distal to the applied pressure;
c) delivering the polynucleotides to the skeletal muscle cell of the limb distal to the applied pressure; and
d) expressing the polynucleotide in the skeletal muscle cell to detectable levels;
wherein said applying, said inserting, said delivering and said expressing do not diminish subsequent use of the limb by the mammal.